New small molecules such as Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the BCL-2 inhibitor venetoclax, and the Phosphoinositol-3-kinase (PI3K) inhibitor idelalisib, are rarely associated with AIHA. The gene discussed is BTK; the disease is autoimmune hemolytic anemia.